21st week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160144014 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE - Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | 2016-05-26 |
20160144015 | BORDETELLA OUTER-MEMBRANE PROTEIN ANTIGENS AND METHODS OF MAKING AND USING THE SAME - An isolated protein or peptide selected from the group consisting of | 2016-05-26 |
20160144016 | SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE - The present invention provides synthetic | 2016-05-26 |
20160144017 | Synthetic Antigen Constructs Against Campylobacter Jejuni - The invention relates to immunogenic synthetic constructs capable of inducing an immune response against | 2016-05-26 |
20160144018 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS - Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed. | 2016-05-26 |
20160144019 | Novel Therapeutic and Diagnostic Means - Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex. | 2016-05-26 |
20160144020 | JOHNSON GRASS ALLERGENIC POLLEN PROTEINS, ENCODING NUCLEIC ACIDS AND METHODS OF USE - Allergenic Johnson Grass proteins, antibodies thereto and encoding nucleic acids are provided, which may be used for the diagnosis and/or therapy of sensitivity to these allergenic proteins or to immunologically cross-reactive allergenic proteins. In particular, the allergenic Johnson grass proteins and nucleic acids may be used for environmental testing for airborne allergens and/or for batch standardization of diagnostic and therapeutic compositions. | 2016-05-26 |
20160144021 | Vaccine Composition And Method Of Use - Described herein is a vaccine composition and methods of use. In one embodiment, the vaccine composition includes RSV-F protein in combination with an adjuvant. In a more particular embodiment, the vaccine composition includes RSV soluble F protein in combination with a lipid toll-like receptor (TLR) agonist. In a more particular embodiment, the adjuvant comprises Glucopyraonsyl Lipid A (GLA). In a further embodiment, the adjuvant comprises GLA in a stable oil-in-water emulsion (GLA-SE). | 2016-05-26 |
20160144022 | MODIFIED MATRIX PROTEINS OF VESICULAR STOMATITIS VIRUS - The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to alanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). These new rVSVs having the mutant M are significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher. | 2016-05-26 |
20160144023 | DRY SOLID ALUMINUM ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF - Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity. | 2016-05-26 |
20160144024 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells - Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment. | 2016-05-26 |
20160144025 | METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES - The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept). | 2016-05-26 |
20160144026 | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases - The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor. | 2016-05-26 |
20160144027 | COMBINATION THERAPY USING C-MET INHIBITOR AND IGF-1R INHIBITOR - A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor. | 2016-05-26 |
20160144028 | COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR - A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor | 2016-05-26 |
20160144029 | Anti-ErbB3 Antibodies and Uses Thereof - The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers. | 2016-05-26 |
20160144030 | TECHNIQUES FOR RELEASE OF MATERIAL INTO AN ENVIRONMENT - Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment. | 2016-05-26 |
20160144031 | Photo-Responsive Compounds - The presently-disclosed subject matter provides photo-responsive compounds and methods of use thereof. The photo-responsive compounds comprise a photolabile molecule and a fluorophore appended to the photolabile molecule. The presently-disclosed subject matter further relates to a drug delivery system that uses red blood cells to deliver photo-responsive compounds for the treatment of disease. | 2016-05-26 |
20160144032 | COMPOSITION FOR NEW BONE FORMATION, AND NEW BONE FORMATION SYSTEM - Provided are a composition for new bone formation and a new bone formation system, which when used to fill a bone treatment site does not effuse from the filled site due to flow of bone marrow fluid or the like, and which can promote formation of new bone at the bone treatment site. By employing a composition for new bone formation containing microparticles of a material that can emit heat in response to an external signal, and a carrier for the microparticles, formation of new bone at the bone treatment site can be promoted. | 2016-05-26 |
20160144033 | CONCENTRATED ACETAMINOPHEN SOLUTION - A concentrated acetaminophen solution is provided that is dissolved in polyethylene glycol (PEG) with trace water. The acetaminophen is present in the PEG at a concentration of at least 200 mg per mL. The composition is useful to deliver or safely store concentrated doses of acetaminophen without degradation of the acetaminophen. | 2016-05-26 |
20160144034 | FORMULATIONS OF BENDAMUSTINE - Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. | 2016-05-26 |
20160144035 | FORMULATIONS OF BENDAMUSTINE - Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. | 2016-05-26 |
20160144036 | TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION - The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. | 2016-05-26 |
20160144037 | ADJUVANT COMPOSITIONS AND RELATED METHODS - The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and an antigen. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided. | 2016-05-26 |
20160144038 | WATER-SOLUBLE SUPRAMOLECULAR COMPLEXES - Water-soluble supramolecular complexes formed from a water soluble block copolymer and at least one associative gelling adjuvant. The copolymer includes at least two blocks of polyethylene oxide and at least one block of polypropylene oxide. The adjuvant has a water solubility less than 0.5 g/100 ml at 20° C. When combined with water, the complexes form a transparent reversely thermo-reversible hydrogel or solution that may be repeatedly hydrated and dehydrated. The hydrogel exhibits improved gelling efficiency and enhanced solubility and/or stability for sparely soluble and insoluble pharmaceutical agents. The complexes are useful in a variety of pharmaceutical and cosmetic products and applications and may be combined with an effective amount of a cosmetic, medicament, or diagnostic in a solid dosage form. | 2016-05-26 |
20160144039 | METHODS FOR ENHANCING STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS - Disclosed herein are methods of enhancing the stability of a sustained pharmaceutical composition comprising an active agent and a polymer and methods of preparing such pharmaceutical compositions with enhanced stability. | 2016-05-26 |
20160144040 | DRUG SUSTAINED RELEASE AGENT BASED ON OLEANOLIC ACID AND A PREPARATION METHOD THEREOF - The present invention relates to the technical field of oleanolic acid drugs and provides a drug sustained release agent based on oleanolic acid and a preparation method thereof. The drug sustained release agent based on the oleanolic acid is applied to drugs with the oleanolic acid as a main drug component and is prepared from the components including a drug carrier, a hydrophilic gel material, a erodible matrix material and an insoluble matrix material, wherein the drug carrier is β-cyclodextrin-chitosan composites, wherein the oleanolic acid is from a plant raw material, and a host-guest inclusion complex is composed of the main drug component and the drug carrier according to the mass ratio of 0.1:0.1-0.1:5. A preparation method comprises the following steps: preparing the inclusion complex, mixing auxiliaries, carrying out compression moulding and the like. The drug sustained release agent based on oleanolic acid has the characteristics of stable drug concentration, high biological activity, good drug solubility and long acting effect. | 2016-05-26 |
20160144041 | CARRIER FOR DELIVERY OF SUBSTANCE TO PHAGOCYTES - An object of the present invention is to provide a low-cost and safe approach to efficient delivery of a substance to phagocytes. In particular, the present invention relates to a carrier for delivery of a substance to phagocytes, the carrier comprising a lactic acid bacterium and/or an extract thereof. | 2016-05-26 |
20160144042 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker. | 2016-05-26 |
20160144043 | METHOD FOR CROSSLINKING HYALURONIC ACID; METHOD FOR PREPARING AN INJECTABLE HYDROGEL; HYDROGEL OBTAINED; USE OF THE OBTAINED HYDROGEL - The present invention relates to a method for crosslinking hyaluronic acid, a method for preparing an injectable hydrogel, the hydrogel thus obtained and its use. | 2016-05-26 |
20160144044 | Carboxymethylcellulose-Peptide Conjugates and Methods for Using the Same - Provided are compositions for repairing an injured tissue. The composition includes carboxymethylcellulose conjugated to an extracellular matrix derived peptide, and a methylcellulose. Also provided are kits and methods for using the subject compositions. | 2016-05-26 |
20160144045 | MULTI-ARM POLYMERIC ALKANOATE CONJUGATES - Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies. | 2016-05-26 |
20160144046 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD - Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the α-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol. | 2016-05-26 |
20160144047 | N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES - The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 2016-05-26 |
20160144048 | Pegylated Hemoglobin and Albumin and Uses Thereof - The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide. | 2016-05-26 |
20160144049 | CARRIERS FOR IMPROVED DRUG DELIVERY - The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties. | 2016-05-26 |
20160144050 | PRODRUGS ACTIVATED BY CASPASE - Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer. | 2016-05-26 |
20160144051 | LOGIC ELEMENT COMPLEX BASED ON BIOMOLECULES (VARIANTS) - The invention relates to the field of logic elements, specifically to logic elements based on biomolecules. The essence of the invention consists in a logic element complex which converts input signals into an output action according to a given logic function. Depending on the output action, the proposed logic element complex can be used both for computational purposes and for various applications in biomedicine, e.g., for diagnostics or therapy of diseases, targeted delivery of a substance to target cells, etc. The technical result when using the invention consists in a logic element complex, for which a plurality of input signals and output actions can be virtually unlimited, said signals and output actions can be different in nature, and, in addition, implementation of a wide range of logic functions for the same input signals is made possible. | 2016-05-26 |
20160144052 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A conjugate of formula (A): | 2016-05-26 |
20160144053 | TREATMENT OF INTRACELLULAR BACTERIAL INFECTION - An intracellular bacterial infection in a plant or animal is treated by administration to a plant cell or animal cell of a particle to which an infectious bacteriophage is covalently attached, wherein the particle is internalised by the cell. Particles with phage attached and compositions comprising the particles are provided. A formulation, for treatment of a bacterial infection, comprises bacteriophage, liquid carrier and adhesive, which dries so that the adhesive adheres the bacteriophage to a surface, one such formulation comprising liquid carrier: 85%-99.98% by weight; bacteriophage: 0.01%-5% by weight; and adhesive: 0.01%-10% by weight. | 2016-05-26 |
20160144054 | Vector(S) Containing an Inducible Gene Encoding a CDK4/CDK6 Inhibitor Useful for Treating Neurodegenerative Disorders or Diseases Associated with an Unscheduled Activation of the Cell Cycle - Described are vectors containing (a) a gene encoding (i) a CDK4/CDK6 inhibitor, preferably p16INK4a, or (ii) an RNA interfering with CDK4 and/or CDK6 expression and/or activity, under the control of an inducible promoter and (b) a gene encoding a transactivator protein for said promoter useful for treating neurodegenerative disorders. These vectors can be transferred into cells where they will exert a protective function to (i) prevent cell death or to (ii) slow down progression of cell death. These vectors can be used in therapeutic applications to prevent neurodegenerative disorders or to slow down their progression with therapeutic efficacy. | 2016-05-26 |
20160144055 | GENE THERAPY VECTOR FOR TREATMENT OF STEROID GLAUCOMA - The presently disclosed subject matter provides an inducible vector comprising a therapeutic gene. In some embodiments a method is provided for treating steroid glaucoma. In some embodiments a method is provided for preventing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a method is provided for reversing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a steroid treatment method is provided. Also provided are pharmaceutical compositions comprising an inducible vector. | 2016-05-26 |
20160144056 | Materials and Methods for the Treatment of Pathological Neovascularization in the Eye - The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD. | 2016-05-26 |
20160144057 | Methods for Expressing a Polynucleotide of Interest in the Retina of a Subject - The present invention relates to methods for expressing a polynucleotide of interest in the retina of a subject. In particular, the present invention relates to a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression. | 2016-05-26 |
20160144058 | IR DYES FOR FLUORESCENCE IMAGING - A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle. | 2016-05-26 |
20160144059 | MICROBUBBLE TETHER FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed. | 2016-05-26 |
20160144060 | Imaging of Meningiomas Using Phenylbenzothiazole, Stilbene, or Biphenylalkyne Derivatives - Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed. In one version of the method, the stilbene derivative is a compound of formula (X): | 2016-05-26 |
20160144061 | Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides - Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. | 2016-05-26 |
20160144062 | USE OF HER2 BINDERS - A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition. | 2016-05-26 |
20160144063 | FRAGRANCE DELIVERY DEVICE, SYSTEM, AND METHOD - A fragrance delivery device, system and method is provided, comprising a housing including a rupture device and an absorbent member receivable in the housing. The system further includes a cartridge insertable within the housing and containing a fragrance medium therein. The rupture device of the housing is engageable with the cartridge to release the fragrance medium from the cartridge into the housing. The absorbent member absorbs the fragrance medium and permeates a fragrance from the fragrance medium to an external environment. | 2016-05-26 |
20160144064 | FRAGRANCE DELIVERY DEVICE, SYSTEM, AND METHOD - A fragrance delivery device, system and method is provided, including a housing including at least one sidewall, a base member coupled with the housing, and an absorbent member receivable in the housing and disposed above the base member. The absorbent member includes at least one contact section. The system further includes an external dispenser containing a fragrance medium therein, wherein the base member receives the fragrance medium from the external dispenser. The absorbent member is engageable with the base member and the fragrance medium is in fluid communication with the at least one contact section. The absorbent member absorbs the fragrance medium and permeates a fragrance from the fragrance medium to an external environment. | 2016-05-26 |
20160144065 | HIGHLY ABSORBENT POLYSACCHARIDE FIBER AND USE THEREOF - The present invention relates to a method for the production of highly absorbent polysaccharide fibers which contain a mixture of cellulose and α(1→3)-glucan as a fiber-forming substance, as well as to the highly absorbent fibers made thereby, and to their use. | 2016-05-26 |
20160144066 | BIOACTIVE FILAMENTARY FIXATION DEVICE - In one embodiment, the present invention is a method of preparing a bioactive filamentary fixation device in situ, including (a) providing a filamentary fixation device including a sleeve member and a filament; (b) providing a physiological solution; (c) providing bioactive material; (d) wetting the sleeve of the fixation device with the physiological solution to produce a wetted sleeve; and (e) applying the bioactive material to the wetted sleeve to coat the sleeve, thus producing a bioactive filamentary fixation device at the time of surgery in situ. | 2016-05-26 |
20160144067 | FILMS AND METHODS OF MANUFACTURE - Embodiments of the present disclosure are directed to perforated polymer films and methods of making the same. In some embodiments, the films are for use with implantable medical devices. In one embodiment there is a flexible body including a polymer film having a first surface and an opposing second surface, the film having a plurality of apertures extending from the first surface to the second surface and a plurality of raised lips protruding from the first surface such that each of the plurality of apertures is surrounded by a one of the plurality of raised lips. In one embodiment, the film comprises a single layer, and in another embodiment, the film can comprise a plurality of layers. In certain embodiments, the film can comprise an adhesive layer. In another embodiment, one or more of the layers may be a drug containing layer and/or a rate controlling layer for drug release. | 2016-05-26 |
20160144068 | Nanocomposite Hydrogels - Provided herein are hemostatic compositions useful for treating wounds in a patient in need thereof. An exemplary hemostatic comprises gelatin or a derivative thereof and silicate nanoparticles. Methods of use, kits comprising the compositions, and a process of making the compositions are also provided. | 2016-05-26 |
20160144069 | SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA - The present invention features a superporous hydrogel scaffold for corneal regeneration or replacement and a method for producing the same. The superporous hydrogel is composed of a poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(methyl methacrylate) (PMMA) copolymer mixed with collagen. The scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis. | 2016-05-26 |
20160144070 | CO-PRECIPITATION OF A THERAPEUTIC AGENT INTO HYDROXYAPATITE COATINGS - A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent. | 2016-05-26 |
20160144071 | BIOMIMETIC COLLAGEN-HYDROXYAPATITE COMPOSITE MATERIAL - The invention relates to: a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e. a length of 30 to 50 nm and a width of 14 to 25 nm, a process of preparing the above biomimetic collagen-hydroxyapatite composite material comprising the steps of a) immersing an at least partially fibrous collagen scaffold including the above mature native collagen fibers in a saturated aqueous solution of saturated Ca | 2016-05-26 |
20160144072 | Mesh Fiber Members and Methods for Forming and Using Same for Treating Damaged Biological Tissue - A mesh fiber member having a plurality of biodegradable fibers, the mesh fiber member being configured to induce modulated healing of damaged biological tissue when deployed proximate thereto. The strands comprise an extracellular matrix (ECM) composition or an ECM-mimicking biomaterial composition, such as poly(glycerol sebacate) (PGS), and can include a biodegradable ECM, polymeric or ECM-mimicking biomaterial composition coating. | 2016-05-26 |
20160144073 | Biological Constructs for Treating Damaged Organs and Tissue - Biological constructs that can be engineered into a variety of shapes and employed to treat, augment and/or support damaged or diseased mammalian organs and/or tissue related thereto. The shapes include jackets and bands that are configured to encase a preselected region of a mammalian organ. | 2016-05-26 |
20160144074 | Biological Constructs for Treating Damaged Organs and Tissue - Biological constructs that can be engineered into a variety of shapes and employed to treat, augment and/or support damaged or diseased mammalian organs and/or tissue related thereto. The shapes include jackets and bands that are configured to encase a preselected region of a mammalian organ. | 2016-05-26 |
20160144075 | BONE MATRIX COMPOSITIONS AND METHODS - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 2016-05-26 |
20160144076 | Mesh Fiber Members and Methods for Forming and Using Same for Treating Damaged Biological Tissue - A mesh fiber member having a plurality of biodegradable fibers, the mesh fiber member being configured to induce modulated healing of damaged biological tissue when deployed proximate thereto. The strands comprise an extracellular matrix (ECM) composition or an ECM-mimicking biomaterial composition, such as poly(glycerol sebacate) (PGS), and can include a biodegradable ECM, polymeric or ECM-mimicking biomaterial composition coating. | 2016-05-26 |
20160144077 | DRUG-COATED BALLOON CATHETER AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to a drug-coated balloon catheter and to a method for producing the same. The balloon of the catheter includes (i) a main membrane, and (ii) an asymmetrical polymer membrane which is applied to an outside of the main membrane and into which at least one pharmaceutical active ingredient is introduced. | 2016-05-26 |
20160144078 | MULTILAYER STRUCTURE AND METHOD OF MANUFACTURING A MULTILAYER STRUCTURE - In some examples, a medical device system a thin film including at least one electrically conductive track extending between at least one electrode and at least one electrical contact, a first and second polymer layer; wherein, at a portion of the thin film between the at least one electrode and the at least one electrical contact, the first polymer layer and second polymer layer surround the at least one electrically conductive track; and at least one discrete ceramic member located between the first and second polymer layers at a portion of the thin film between the at least one electrode and the at least one electrical contact, wherein the at least one discrete ceramic member does not surround the at least one conductive track, and wherein the at least one discrete ceramic member is configured to increase adhesion between the first polymer layer and second polymer layer. | 2016-05-26 |
20160144079 | MODIFICATION OF SURFACES FOR FLUID AND SOLID REPELLENCY - Articles, methods of making, and uses for modifying surfaces for liquid repellency are disclosed. The liquid repellant surfaces comprise a surface comprising an anchoring layer. The anchoring layer, which forms an immobilized molecular anchoring layer on the surface, has anchoring molecules, where each anchoring molecule has a head group that is covalently linked to the surface and a functional tail group. The anchoring molecules are crosslinked to each other to form a crosslinked network. The functional tail group has an affinity for a lubricating liquid, which is applied to the treated surface to form a lubricating layer. The anchoring layer and replenishable lubricating liquid are held together by non-covalent attractive forces. Together, these layers form an ultra-repellant slippery surface that repels certain immiscible liquids and prevents adsorption, coagulation, and surface fouling by components contained within. | 2016-05-26 |
20160144080 | PEO COATING ON MG SCREWS - The present invention relates generally to a bio-degradable implant based on magnesium having a reduced corrosion rate and to a method for the production of such an implant. It is a a method for treating a surface of a bio-degradable metallic implant comprising the following steps: providing a dispersed system comprising a colloid-dispersed apatite and adding an apatite powder to the dispersed system, subjecting an implant to the dispersed system such that a surface of the implant which is to be treated is immersed in the dispersed system wherein the implant comprises a magnesium based alloy, applying an AC voltage difference between the implant as a first electrode and a second electrode positioned in the dispersed system for generating a plasma electrolytic oxidation on the immersed surface of the implant so that the immersed surface is converted to an oxide film which is at least partially covered by apatites formed by the colloid-dispersed apatite and the apatite powder. The evolution of corrosion induced hydrogen gas evolution is decreased and osseointegration is improved. | 2016-05-26 |
20160144081 | CANISTER MEMBRANE FOR WOUND THERAPY SYSTEM - A portable system for subatmospheric pressure therapy in connection with healing a surgical wound includes a wound dressing dimensioned for positioning relative to a wound bed of a subject and a collection canister in fluid communication with the wound dressing. The canister includes a first vacuum chamber for drawing a vacuum and a second fluid chamber for collecting fluids removed from the wound dressing under the vacuum. The vacuum chamber may have a vacuum and a power source. The canister further includes a hydrophobic membrane separating the first and the second fluid vacuum chambers. The hydrophobic membrane is dimensioned to span a major portion of the cross-sectional area of the canister. The hydrophobic membrane may be dimensioned to substantially span an internal dimension of the collection canister. The hydrophobic membrane may include one or more outwardly extending lobes. The outwardly extending lobes may be arranged in staggered relation. The hydrophobic membrane may be releasably mountable to the canister, and, may be supported within a divider separating the first vacuum chamber and the second fluid chamber. | 2016-05-26 |
20160144082 | SUSTAINED VARIABLE NEGATIVE PRESSURE WOUND TREATMENT AND METHOD OF CONTROLLING SAME - Disclosed herein are systems and methods for providing reduced or negative pressure, and more particularly cyclical reduced pressure, to treat a wound. The system can include a wound dressing, a fluid collection container, a suction source, filters, and conduits. In addition, the system can include a control device and sensors. The sensors may be configured to monitor certain physiological conditions of a patient such as temperature, pressure, blood flow, blood oxygen saturation, pulse, cardiac cycle, and the like. Application of cyclical reduced pressure between two or more values below atmospheric pressure may be synchronized with the physiological conditions monitored by the sensors. Certain embodiments of the system utilize an air reservoir and one or more valves and pressure sensors or gauges to allow for rapid cycling of the level of reduced pressure within the wound dressing between two or more reduced pressure values. | 2016-05-26 |
20160144083 | NASAL ASPIRATOR DEVICE - A nasal aspirator device adjustably limits distance of insertion into a nasal cavity. The device includes a resiliently compressible bulb having an interior space. A first end of a tube is coupled to the bulb and a second end of the tube is positioned in spaced relationship to the bulb. The tube is in fluid communication with the interior space of the bulb. A ridge is coupled to and extends around an outer surface of the tube. The tube is insertable through an aperture in a guard such that the ridge abuts the guard wherein the guard is inhibited from sliding past the ridge towards the bulb. | 2016-05-26 |
20160144084 | WOUND DRESSING AND METHOD OF TREATMENT - Embodiments disclosed herein are directed to negative pressure treatment systems and wound dressing systems, apparatuses, and methods that may be used for the treatment of wounds. In particular, some embodiments are directed to improved wound dressings comprising a bridge portion connecting two or more portions of an absorbent layer that facilitates trimming of the wound dressing to suitable sizes. Some embodiments provide for trimming the dressing in a gap between two or more portions of an absorbent layer and sealing the exposed portion of dressing after trimming when the dressing is applied to skin surrounding a wound. | 2016-05-26 |
20160144085 | FLUID TRANSPORT DRESSING - The present disclosure relates to a fluid transport dressing for a negative pressure wound treatment system. The fluid transport dressing comprises a plurality of sealed chambers comprising chamber fluid. | 2016-05-26 |
20160144086 | Device for Harvesting, Processing and Transferring Adipose Tissue - The present disclosure provides devices and methods for harvesting and processing tissue from patients for grafting. The devices can include a tissue collection chamber for ascetically collecting, processing, and/or re-implanting adipose tissue. | 2016-05-26 |
20160144087 | HEART ASSIST DEVICE - A heart assist device comprising a rotary pump housing having a cylindrical bore, a pumping chamber and a motor stator including an electrically conductive coil located within the housing and surrounding a portion of the cylindrical bore. A rotor has a cylindrical shaft, at least one impeller appended to one end of the shaft, and a plurality of magnets located within the shaft. The rotor shaft is positioned within the housing bore with the magnets opposite the motor stator, and the impeller is positioned within the pumping chamber. The housing bore is closely fitted to the outer surface of the shaft forming a hydrodynamic journal bearing, with the pumping chamber and journal bearing connected by a leak path of blood flow between the pumping chamber and the journal bearing. A backiron of the motor stator attracts the rotor magnets to resist longitudinal displacement of the rotor within the housing during operation. The relative orientation of positions of the inflow, outflow, and leakage flow paths may be varied within the pump, such as to accommodate different intended methods for implantation and/or use. | 2016-05-26 |
20160144088 | PUMP OR ROTARY CUTTER FOR OPERATION IN A FLUID - The invention relates to a fluid pump or rotatary cutter having at least one first element ( | 2016-05-26 |
20160144089 | PUMP AND METHOD FOR MIXED FLOW BLOOD PUMPING - A blood pump includes a housing and a rotor within the housing configured to rotate along an axis. The rotor may include a hub, the hub having regions with blades and regions without blades. The regions without blades may have a constant outer diameter and may extend along at least one fourth the length of the hub. The regions with blades may have an increasing outer diameter. Blades may be disposed on a downstream end region of the hub and extend downstream of the hub. Blades may begin approximately halfway along the axial length of a motor stator located about a hub and extend downstream of the motor stator. Blades may have portions that produce axial fluid flow and radial fluid flow with improved flow characteristics. | 2016-05-26 |
20160144090 | AUTO LOADING AND UNLOADING PERISTALTIC PUMP APPARATUS - A peristaltic pumping apparatus for use in blood processing procedures, comprising: a pump rotor rotatable about a rotational axis and a pump raceway circumferentially spaced about the axis; a pump cap disposed atop the pump rotor, the pump cap having a finger configured to engage a tubing loop of a length of tubing at a time of loading the tubing and guide the tubing loop within the raceway along the length of the tubing loop; and wherein the pump cap further comprises a tensioning wall disposed laterally opposite the finger, the tensioning wail configured to engage a length of the tubing loop at a time of unloading the tubing and provide tension to the tubing length as the tubing loop exits the raceway. | 2016-05-26 |
20160144091 | ELECTROACTIVE ACTUATORS - The invention relates to actuators based on electroactive polymeric materials for use in pumping fluids or in other applications where a contractile actuation is required, in particular although not necessarily exclusively for use in vascular pulsation devices such as a variable aortic tension device. Embodiments disclosed include an actuator ( | 2016-05-26 |
20160144092 | FIDUCIAL POINT OPTIMIZATION - A flow rate of blood through an implantable blood pump is determined based on a parameter related to the flow, such as a parameter related to thrust on the rotor of the pump. An amount of current supplied to the pump is used to determine each of a first flow rate value and second flow rate values. Each of the first and second flow rate values, in combination with the parameter related to thrust on the rotor of the pump, are used to calculate a flow rate of blood through the pump. | 2016-05-26 |
20160144093 | MEDICAL TREATMENT SYSTEM AND METHODS USING A PLURALITY OF FLUID LINES - A medical treatment system, such as a peritoneal dialysis system, may include a control and other features to enhance patient comfort and ease of use. For example, a cycler device may include a heater bag receiving section and a lid mounted to cover and uncover the heater bag receiving section, potentially enabling faster heating of a dialysate. A user interface may be moveable to be received into the receiving section and covered by the lid, if desired. The system may detect anomalous conditions, such as tilting of a housing of the system, and automatically recover without terminating a treatment. The system may include noise reduction features, such as porting pneumatic outputs to a common chamber, and others. The system may also automatically detect any one of several different solution lines connected to the system, and control operation accordingly, e.g., to mix solutions provided by two or more lines and form a needed dialysate solution. A cassette control surface may be arranged to have one or more ports that can detect a presence of a liquid, e.g., to identify if a cassette is leaking or has otherwise been compromised. | 2016-05-26 |
20160144094 | COMPOSITIONS, METHODS, AND DEVICES FOR DIALYSIS - Compositions of peritoneal dialysis solutions and metabolizing enzymes, and their uses to treat disorders associated with elevated levels of metabolites are disclosed. Animal models of hyperoxalemia are also disclosed. | 2016-05-26 |
20160144095 | TREATMENT DEVICE FOR PLASMA VIRUS INACTIVATION - A device and method can be used for clinical virus inactivation treatment to automatically, continuously and cyclically treat plasma of a patient in a closed system. The disclosed plasma treatment device may be used for an anti-viral agent such as, for example, methylene blue photochemical plasma virus inactivation. The plasma treatment device can perform real-time treatment to the plasma in the closed system on the basis of the principle of plasma exchange and can realize real-time back-transfusion during treatment. | 2016-05-26 |
20160144096 | AN APPARATUS FOR EXTRACORPOREAL BLOOD TREATMENT AND A RELATED CONTROL METHOD - An apparatus for extracorporeal blood treatment ( | 2016-05-26 |
20160144097 | FLUID CONVEYANCE SAFETY DEVICES, METHODS, AND SYSTEMS - The disclosed subject matter includes a structure and method for making a dual-lumen needle from single lumen needles to take advantage of the much higher economies of scale. Variations include two needles joined by a flow junction and one needle and a single cannula joined by a flow junction. In addition disclosed are methods of using a dual-lumen needle in a two needle access for blood treatment is disclosed in which at least venous flow is provided through a dual-lumen needle with arterial flow just sufficient to provide air infiltration detection in the event of withdrawal of the dual-lumen needle. | 2016-05-26 |
20160144098 | MEMBRANE SEPARATION AND WASHING DEVICES, SYSTEMS AND METHODS EMPLOYING SAME, AND DATA MANAGEMENT SYSTEMS AND METHODS - A method of separating blood into two or more components and subsequently washing a component, comprising providing a blood storage container containing an initial blood composition, and a blood separation circuit comprising a separator. The method also comprises separating and washing cellular material within the same blood separation circuit. | 2016-05-26 |
20160144099 | APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL AND PREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION - An apparatus and method for preparing a pharmaceutical for transient application includes a tray having a sealed compartment, a vial of an ophthalmic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe that are all contained together in a single package. The component parts of the apparatus are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the scaled compartment of the tray by a suction force produced by the syringe. In the tray compartment, the reconstituted drug is absorbed in at least one absorbent pad. The absorbent pads may come in multiple shapes and or/sizes. The tray is opened to remove the pad and the absorbed drug from the tray compartment for use of the pad in transient application of the drug. | 2016-05-26 |
20160144100 | MICRO-NEEDLE DRUG DELIVERY SYSTEMS - Generally, devices, systems and methods of using one or more needle(s) or micro-needle arrays are described in which a shift of fluid volume from a first expansion member position to a second expansion member position drives delivery of the fluid, which can be a drug or drug solution, through the needle(s) or micro-needle arrays. | 2016-05-26 |
20160144101 | MECHANICAL INJECTION PUMP AND METHOD OF USE - A mechanical injection pump wearable by a user to deliver a first fluid and a second fluid, including: a pump body having a first fluid chamber to hold the first fluid and a second fluid chamber to hold the second fluid; a common connector having a first inlet, a second inlet, and a common outlet; a first fluid system including the first fluid chamber, a first button drive connected to the first fluid chamber, and first fluid delivery path between the first fluid chamber and the first inlet; and a second fluid system including the second fluid chamber, a second button drive connected to the second fluid chamber, and second fluid delivery path between the second fluid chamber and the second inlet. Force by the user on the button drive increases pressure within the fluid chamber to drive a predetermined volume of the fluid from the fluid chamber. | 2016-05-26 |
20160144102 | FLUID CONDUIT ASSEMBLY WITH AIR VENTING FEATURES - A fluid conduit assembly for delivery of a medication fluid, and an associated fluid delivery system, are disclosed here. The fluid conduit assembly includes a trapping chamber having an interior volume to receive the medication fluid. The fluid conduit assembly also includes an inlet in fluid communication with the interior volume, a first outlet arrangement for the trapping chamber, and a second outlet arrangement for the trapping chamber. The first outlet arrangement accommodates flow of liquid from the interior volume, while inhibiting flow of gas from the interior volume. The second outlet arrangement accommodates flow of gas from the interior volume, while inhibiting flow of liquid from the interior volume. | 2016-05-26 |
20160144103 | SYSTEMS AND METHODS FOR FLUID INFUSION DEVICE WITH AUTOMATIC RESERVOIR FILL - Systems and methods for a fluid reservoir for use with a fluid infusion device, which is automatically filled are provided. The fluid reservoir includes a barrel having a proximal end and a distal end. The fluid reservoir also includes a stopper received in the barrel and movable within the barrel from the distal end to the proximal end to dispense a fluid from a passageway of the barrel. The fluid reservoir includes at least one engagement feature defined along a portion of a perimeter of the barrel near the proximal end that removably couples the fluid reservoir to the fluid infusion device. | 2016-05-26 |
20160144104 | SYSTEMS AND METHODS FOR FLUID INFUSION DEVICE WITH AUTOMATIC RESERVOIR FILL - Systems and methods for a fluid reservoir for use with a fluid infusion device which is automatically filled are provided. A set connector for use with a fluid reservoir of a fluid infusion device includes a body for defining a fluid flow path out of the fluid reservoir. The body includes at least one locking tab that cooperates with a portion of the fluid infusion device to removably couple the body to a proximal end of the fluid reservoir. The body is movable between a first position, in which the fluid flow path is obstructed, and a second position, in which the fluid flow path is open. | 2016-05-26 |
20160144105 | VIAL TRANSFER AND INJECTION APPARATUS AND METHOD - Drug delivery system, injection device, transfer apparatus, vial holder and method of administering and transferring are disclosed. The system may include transfer apparatus and an injection device. The transfer apparatus may have receiving stations for a drug source, such as a vial or vial holder, and for an injection device, and fluid flow pathways for transferring drugs from the source into the injection device. The injection device may include an expandable elastic bladder and an injection cannula that is movable between a plurality of positions. | 2016-05-26 |
20160144106 | INFUSION SET INSERTION DEVICE AND METHOD OF USE - An infusion set insertion device and method of use with an insertion device for an infusion set having an infusion set body including: a barrel defining a pull handle cavity; a pull handle slideably disposed in the pull handle cavity, the pull handle having an outer surface and defining an infusion set cavity and a release button cavity, the pull handle having a cocked position and an advanced position relative to the barrel; a release button slideably disposed in the release button cavity, the release button having a loaded position and a released position relative to the pull handle; and a driver operable to move the pull handle from the cocked position to the advanced position; wherein the release button extends a first axial distance beyond the outer surface when in the loaded position and extends a second axial distance into the infusion set cavity when in the released position. | 2016-05-26 |
20160144107 | Systems for Isolation of a Needle-based Infusion Set - A safety needle assembly of an infusion set for infusing fluids into a subcutaneously implanted access port is disclosed. The needle assembly is configured to prevent fluid/vapor escape therefrom so as to reduce or prevent fluid exposure to a clinician using the needle assembly. In one embodiment, the needle assembly comprises a handle portion including a needle extending therefrom, the needle defining a lumen for passage of a fluid therethrough. The needle assembly also includes a safety assembly defining a needle hole through which the needle initially extends. The safety assembly is selectively and axially slidable along the needle in order to shield a distal tip of the needle and prevent user contact therewith. A fluid isolation component is included in the safety assembly for isolating fluid escape from the needle to prevent exposure to a clinician. | 2016-05-26 |
20160144108 | SYSTEMS AND METHODS FOR FLUID INFUSION DEVICE WITH AUTOMATIC RESERVOIR FILL - Systems and methods for a fluid reservoir associated with a fluid infusion device, which is automatically filled are provided. The fluid infusion device includes a source of input and a fluid reservoir system including the fluid reservoir having a barrel and a stopper disposed within the barrel. The fluid infusion device also includes a drive system coupled to the stopper of the fluid reservoir system and a control module that outputs one or more control signals to the drive system to move the stopper to fill the barrel of the fluid reservoir with a fluid based on the input. | 2016-05-26 |
20160144109 | DEVICES, ASSEMBLIES, AND METHODS FOR CONTROLLING FLUID FLOW - Connector assemblies are provided for controlling flow in a fluid line that include an outer shell, an inner housing, and a tubular member. The inner housing is disposed within the outer shell and includes a boss disposed adjacent a first end of the outer shell. The inner housing is movable axially within the outer shell between first and second positions when a device is connected to the first end. The tubular member is carried by the inner housing and includes a fluid passage extending between a second end of the outer shell. The tubular member moves axially as the inner housing moves between the first and second positions, and cam features on the outer shell and the tubular member cause the tubular member to rotate as the inner housing moves between the first and second positions, thereby opening a fluid path between the fluid passage and the first end. | 2016-05-26 |
20160144110 | CONNECTOR AND TRANSFUSTION SET - A connector provided with a housing which defines an insertion section into which a male connector is inserted from the outside and a flow path communicating with the insertion section and an elastic valve body which has a slit and blocks the insertion section. The housing includes a tip receiving section formed on an inner wall defining the flow path, the tip receiving section receiving a tip of the male connector inserted through the slit of the elastic valve body. The tip receiving section is formed on only a part of the inner wall in a cross section that is perpendicular to an insertion direction of the male connector and includes at least a part of the tip receiving section. | 2016-05-26 |
20160144111 | Sensor Device for Use in a Medical Fluid Delivery System - A sensor device for use in a medical fluid delivery system, or an infusion pump device, comprises a fluidic chamber with a deformable cover closing at least an area of the chamber and an optical detection system comprising at least one light emitter for emitting one or more incident light beams and a sensor unit for monitoring one or more reflected light beams is presented. In a pressurized state of the fluidic chamber, the deformable cover is deformed such that it forms an inflexion point area within the deformed cover. The one or more incident light beams emitted by the light emitter are directed on the cover such that the one or more incident light beams are reflected essentially in the inflexion point area. | 2016-05-26 |
20160144112 | ADJUSTING DEVICE FOR A FLOW CONTROLLER - An adjusting device for adjusting the flow rate of a medicinal fluid-conveying system, said device having a selection wheel for selecting one of a number of possible flow rates, having an adjusting disc connected to said selection wheel for adjusting the selected flow rate, and having a catching nose that cooperates with the outer edge of the adjusting disc, is improved in that the adjusting disc has a star shape. | 2016-05-26 |
20160144113 | Methods and systems for controlling medical environments - A system for controlling an environment of a patient undergoing a surgical procedure is provided. The system includes a conduit configured to channel fluids towards the patient, a sensor configured to measure at least one operating parameter of the fluid being channeled to the patient, an effector configured to change the operating parameter of the fluid, and a controller configured to selectively activate the effector based on a signal received from the sensor. | 2016-05-26 |